Trial Information

Summary: Comparison of Antipsychotics for Metabolic Problems (CAMP) in the Treatment of People with Schizophrenia or Schizoaffective Disorder

Clinical Management of Metabolic Problems in Patients with Schizophrenia: Switching to Aripiprazole versus Continued Treatment with Olanzapine, Quetiapine, or Risperdone

Study design is a multi-site, single-blind (rater) randomized controlled trial in patients with schizophrenia or schizoaffective disorder comparing treatment with the following medications: olanzapine, quetiapine, risperidone, and aripiprazole. The study will enroll patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease in spite of adequate control of symptoms on their current antipsychotic medication. Patients who are taking olanzapine, quetiapine, or risperidone and who have a body-mass index (BMI) greater than or equal to 27 and non-HDL cholesterol greater than or equal to 160 mg/dl may be eligible. All treatments will be open label. Patients will be followed for up to 6 months.

Patient Inclusion Criteria:

1. Male or females 18 - 65 years of age
2. Diagnosed with schizophrenia or schizoaffective disorder
3. Currently treated with olanzapine, quetiapine or risperidone
4. BMI = 27
5. Non-HDL cholesterol = 160mg/dL

1. Diabetes (FBS = 126) or treatment with oral hypoglycemic drug or insulin
2. Non-HDL cholesterol > 300 mg/dL
3. Serum triglycerides > 500 mg/dL
4. Known hypersensitivity to aripiprazole
5. Taking weight loss medications

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.